Literature DB >> 3735062

Fundamental pharmacokinetic properties of biperiden: tissue distribution and elimination in rabbits.

K Yokogawa, E Nakashima, F Ichimura, T Yamana.   

Abstract

The pharmacokinetics of biperiden in rabbits were examined at three doses (0.2, 0.8, and 3.2 mg/kg i.v.). The data were interpreted in terms of a three-compartment open model with a linear excretion rate. The serum unbound fraction and the blood-to-plasma concentration ratio were determined as 0.39 and 1.2, respectively, over a wide concentration range (25-10000 ng/ml). Rapid and complete absorption from the injection site in muscle to the systemic circulation was observed. The bioavailability of muscular injection was unity. The hepatic extraction ratio was 0.94, and the high plasma clearance could be explained in terms of hepatic blood flow rate-limited elimination. The major tissues in which biperiden was distributed were fat and muscle. The highest tissue-to-plasma partition coefficient in the steady-state was obtained for the lung. These three tissues comprised 56% of the total distribution volume.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3735062     DOI: 10.1248/bpb1978.9.409

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  3 in total

1.  Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.

Authors:  K Yokogawa; S Iwashita; A Kubota; Y Sasaki; J Ishizaki; M Kawahara; R Matsushita; K Kimura; F Ichimura; K Miyamoto
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Relationships in the structure-tissue distribution of basic drugs in the rabbit.

Authors:  K Yokogawa; E Nakashima; J Ishizaki; H Maeda; T Nagano; F Ichimura
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

3.  Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

Authors:  H Matsuo; A Matsui; R Nasu; H Takanaga; N Inoue; F Hattori; H Ohtani; Y Sawada
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.